GlassScriptPhysician profile
Mary E Booth
NPI 1083232771
$2,073.89
in general payments reported to CMS, 2019-2025
15 companies · $17.47 in 2025
The $17.47 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $541 · 2022: $206 · 2023: $713 · 2024: $597 · 2025: $17.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $303.66 | 2023-2024 | Breztri, Airsupra |
| Amgen INC. | $280.07 | 2021-2023 | Otezla |
| Abbvie INC. | $223.15 | 2022-2025 | |
| Genzyme Corporation | $200.02 | 2024 | |
| Glaxosmithkline, LLC. | $197.90 | 2022-2023 | Bexsero |
| Regeneron Healthcare Solutions, INC. | $129.46 | 2023 | Dupixent |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107.91 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.23 | 2021 | |
| Novo Nordisk INC | $93.34 | 2024 | Wegovy |
| Neurelis, INC. | $86.57 | 2023 | Valtoco |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $78.88 | 2024 | |
| Axsome Therapeutics, INC. | $78.63 | 2023 | Auvelity |
| Viiv Healthcare Company | $75.01 | 2021 | |
| Janssen Pharmaceuticals, INC | $63.61 | 2021 | |
| Itamar Medical INC | $57.45 | 2023 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Booth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.